Business ❯ Pharmaceutical Industry

Market Analysis

Sales Projections Drug Sales Sales Forecast Revenue Projections Drug Development Sales Forecasts Drug Market Stock Performance Investor Relations Revenue Forecasting

FDA Approves First Therapy for Acquired Hypothalamic Obesity, Expanding Rhythm’s Imcivree

The decision follows a late-stage study that showed a 15.8% BMI reduction at 52 weeks compared with a 2.6% increase on placebo.

Bayer’s Asundexian Cuts Recurrent Stroke by 26% in Phase III Without Added Major Bleeding

Sanofi’s Venglustat Notches Gaucher Type 3 Phase 3 Win, Misses Fabry Pain Endpoint

German Insurer TK Sees Up to €11 Billion Annual Savings From Drug Pricing Reforms

FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer’s Agitation, Sets April 30 PDUFA Date

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

Orexin-2 Agonists Lift Wakefulness in Narcolepsy as Takeda Leads With Late-Stage Wins

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

UK Grants First Global Approval for GSK’s Blenrep in Two Combination Therapies

EU Regulators Reject Eli Lilly's Alzheimer's Drug Over Safety Concerns

Weight Loss Industry Transformed by New Drugs and Emerging Alternatives

Amgen's Weight-Loss Drug Shows Promise but Faces Investor Skepticism

AstraZeneca Under Chinese Compliance Probe; Lung Cancer Drug Trial Results Disappoint